Via Ritzau - din kommunikationsplatform

Thomas Emil Andersens tværfaglige forskning indenfor mikrobiologien vil fortsætte i den nye stilling, og hans erfaring fra de seneste 20 år vil hjælpe med at løfte OUH og SDU’s forsknings- og innovationsstrategi.

The post hoc analysis investigated treatment responses in a patient subgroup with moderate to severe Chronic Hand Eczema (CHE) treated with delgocitinib cream for 16 weeks in the DELTA 1 2 phase 3 trials.(1) Late-breaking presentation showcased that delgocitinib cream produced a deep, consistent and/or maintained response in a subgroup of patients with moderate to severe Chronic Hand Eczema (CHE).(1) Separate data presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting evaluated systemic exposure in patients following high use of delgocitinib cream to treat moderate to severe CHE.(2)

New research from Denmark reveals that a mother’s diet during pregnancy—characterised by a Western dietary pattern high in fat and sugar and low in fresh ingredients—may increase the risk of neurodevelopmental disorders such as ADHD and autism in children. Researchers see potential for targeted dietary interventions during pregnancy to reduce this risk.

Forskning viser, at en reduceret mængde kulhydrat og en øget mængde protein og fedt i kosten nedsætter fedtindholdet i leveren og blodet hos personer med type 2-diabetes. Hermed reduceres risikofaktorer for udvikling af hjertekarsygdomme og sygdom i leveren. Forbedringerne er uafhængige af, om man taber sig i vægt. Sådan lyder konklusionerne fra et nyt studie udført på Bispebjerg Hospital og Institut for Idræt og Ernæring ved Københavns Universitet.

Partners form non-exclusive collaboration to expand research efforts and develop new treatments for Epidermolysis Bullosa (EB). The partnership leverages DEBRA Research’s focus on patient care and pharma experience and LEO Pharma’s extensive medical dermatology experience. Munich, Germany, and Ballerup, Denmark, 5 February 2025 – DEBRA Research GmbH, a non-profit organization dedicated to advancing research, advocacy, and support for those affected by Epidermolysis Bullosa (EB) and LEO Pharma, a global leader in medical dermatology, today announced a non-exclusive strategic partnership. This collaboration aims to enhance scouting capabilities and provide additional capacity to accelerate the development of life-changing therapies for EB. The partners are committed to driving transformative progress for EB patients and their families, and to deliver innovative medicines for this serious skin disease with no approved treatment options. “We are pleased to announce our non-exclusive partne

The phase 3 clinical trial (DELTA TEEN) with Anzupgo® in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate, achieved primary and all key secondary endpoints compared to cream vehicle.(1) CHE can significantly affect the quality of life for adolescent patients.(2) There are currently no approved treatment options specifically indicated for moderate to severe CHE in the adolescent patient population.

Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields

Andernach – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies.

Hospitalets forskere har netop modtaget bevillinger for i alt 1.963.000 kr. fra Region Midtjyllands Sundhedsvidenskabelige Forskningsfond.

null

Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.

Aktuel forskning fra Syddansk Universitet viser, at gulerødder kan regulere blodsukkeret og styrke tarmfloraen – en kombination, der potentielt kan gavne personer med type 2-diabetes.

With the launch of the Ambu® SureSight™ Connect solution, Ambu offers clinicians the only airway visualisation and pulmonology offering that features a one-lung ventilation solution and includes all the devices recommended for intubation and airway assessment.

Lektor PhD. Per Bendix Jeppesen, fra Aarhus Universitetshospital fremhæver KaLOHAS® grønkålspulvers sundhedspotentiale

Tusindvis af danskere lever med kroniske smerter efter at have fået nyt knæ. Nu viser et forsøg fra Aalborg Universitet, at undervisning i smerteforståelse har en positiv effekt på patienternes smerter. Derfor bør smerteundervisning tænkes ind som et tilbud til de mange, der føler sig ladt i stikken.

Det kommende hospital for børn, unge og gravide på Rigshospitalet – Mary Elizabeths Hospital – har vundet en Danish Design Award for arbejdet med designkoncepter for hospitalsoplevelsen.

The Swiss Agency for Therapeutic Products, Swissmedic, has approved Anzupgo®, making it the first topical pan-Janus kinase (JAK) inhibitor specifically indicated for the treatment of moderate to severe Chronic Hand Eczema (CHE) in adults who have had an inadequate response to topical corticosteroids, or for whom potent to very potent topical corticosteroids are not advisable.(1) The approval will bring a new treatment option to approximately 4.7% of adults in Switzerland living with CHE, a condition with a high unmet need for which no specifically approved topical treatment was previously available.(2,3) In addition to the results of the DELTA 1,2 and 3 trials, the marketing approval is supported by the head-to-head DELTA FORCE trial of Anzupgo against oral alitretinoin capsules, the only other existing specifically approved treatment for severe CHE.(4-7)

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.

Q3 2024 Trading Update (Unaudited)

Efter Europa Kommissionens produktgodkendelse i september bliver Danmark det næste og kun andet land i verden, hvor LEO Pharma lancerer sit nyeste lægemiddel, Anzupgo® (delgocitinib) creme, efter lanceringen i Tyskland tidligere på måneden. (1) Anzupgo® creme er den første godkendte topikale behandling for voksne med moderat til svært kronisk håndeksem, hvor topikale kortikosteroider er utilstrækkelige eller uhensigtsmæssige. (1) Lanceringen giver en ny behandlingsmulighed for de mange voksne danskere, som lever med moderat til svært kronisk håndeksem, som er en af de mest udbredte kroniske inflammatoriske hudsygdomme, der rammer 4,7% af befolkningen. (2,3)